Dietary Curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity
|Obesity is closely associated with development of several chronic diseases, including myocardial infarction, stroke, type 2 diabetes mellitus and cancer. It is also associated with substantially decreased health-related quality of life and increased medical expenditures.|
A large body of evidence is available suggesting that a large component of obesity-associated pathophysiology may stem from a low-grade pro-inflammatory state. Newer approaches have to be developed to deal with large burden imposed by obesity on the welfare of society, to reduce its occurrence as well as reverse its detrimental physiological alterations.
Therefore, therapeutic management of diabetes and related complications with compounds that attenuate the inflammatory response would be helpful. Curcumin has been known to inhibit activation of the TLR-4 and NF-ĸB pro-inflammatory signaling pathways, which are implicated in the pathogenesis of type 2 diabetes as well.
To investigate whether Curcumin could attenuate the pro-inflammatory, endocrine and metabolic consequences of obesity in genetically obese Lep ob/ob mice.
Results and Discussion:
Curcumin was effective in reversing many of the inflammatory and metabolic derangements associated with obesity and improved glycemic control in mouse models of type 2 diabetes. Thus, warranting further investigation as a novel adjunctive therapy for type 2 diabetes in humans.